CY1119402T1 - Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες - Google Patents

Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες

Info

Publication number
CY1119402T1
CY1119402T1 CY20171100071T CY171100071T CY1119402T1 CY 1119402 T1 CY1119402 T1 CY 1119402T1 CY 20171100071 T CY20171100071 T CY 20171100071T CY 171100071 T CY171100071 T CY 171100071T CY 1119402 T1 CY1119402 T1 CY 1119402T1
Authority
CY
Cyprus
Prior art keywords
antibacterial agents
kinolin
products
compound
bacterial infection
Prior art date
Application number
CY20171100071T
Other languages
Greek (el)
English (en)
Inventor
Anil Koul
Koenraad Jozef Lodewijk Andries
Jérome Emile Georges Guillemont
Magali Madeleine Simone Motte
David Francis Alain LANÇOIS
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119402(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1119402T1 publication Critical patent/CY1119402T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
CY20171100071T 2005-06-28 2017-01-18 Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες CY1119402T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05105755 2005-06-28

Publications (1)

Publication Number Publication Date
CY1119402T1 true CY1119402T1 (el) 2018-03-07

Family

ID=35447198

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100071T CY1119402T1 (el) 2005-06-28 2017-01-18 Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες

Country Status (31)

Country Link
US (1) US20130030016A1 (enExample)
EP (1) EP1898909B1 (enExample)
JP (1) JP5193857B2 (enExample)
KR (1) KR101329587B1 (enExample)
CN (1) CN101252927B (enExample)
AP (1) AP2547A (enExample)
AR (1) AR054804A1 (enExample)
AU (1) AU2006263882B2 (enExample)
BR (1) BRPI0613999B8 (enExample)
CA (1) CA2612614C (enExample)
CY (1) CY1119402T1 (enExample)
DK (1) DK1898909T3 (enExample)
EA (1) EA014431B1 (enExample)
ES (1) ES2610472T3 (enExample)
HR (1) HRP20170044T1 (enExample)
HU (1) HUE030264T2 (enExample)
IL (1) IL188395A (enExample)
JO (1) JO3322B1 (enExample)
LT (1) LT1898909T (enExample)
MX (1) MX2008000079A (enExample)
MY (1) MY173664A (enExample)
NO (1) NO341285B1 (enExample)
NZ (1) NZ564340A (enExample)
PL (1) PL1898909T3 (enExample)
PT (1) PT1898909T (enExample)
RS (1) RS55601B1 (enExample)
SG (1) SG166798A1 (enExample)
TW (1) TWI413520B (enExample)
UA (1) UA88701C2 (enExample)
WO (1) WO2007000434A1 (enExample)
ZA (1) ZA200711148B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2970B1 (en) 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JP5397881B2 (ja) * 2008-09-04 2014-01-22 昇一 城武 グラム陽性細菌用抗菌剤及び抗菌活性増強剤
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
AU2013254670B2 (en) 2012-04-27 2017-03-30 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
JP7514763B2 (ja) * 2017-10-13 2024-07-11 ザ ユニバーシティー オブ クイーンズランド 亜鉛イオノフォアおよびその使用
CN110606825A (zh) * 2019-10-30 2019-12-24 成都海杰亚医药科技有限公司 一种制备吡啶-2-硫醇的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
DK2301544T3 (da) * 2002-07-25 2013-01-02 Janssen Pharmaceutica Nv Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
EP1753427B1 (en) * 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
EA200800151A1 (ru) 2008-06-30
CA2612614C (en) 2017-07-25
US20130030016A1 (en) 2013-01-31
CN101252927A (zh) 2008-08-27
LT1898909T (lt) 2017-02-10
DK1898909T3 (en) 2017-02-06
HRP20170044T1 (hr) 2017-03-10
AU2006263882B2 (en) 2012-12-13
IL188395A (en) 2012-05-31
AR054804A1 (es) 2007-07-18
JP2008546824A (ja) 2008-12-25
MY173664A (en) 2020-02-14
AP2547A (en) 2012-12-26
CN101252927B (zh) 2014-01-01
IL188395A0 (en) 2008-08-07
BRPI0613999A2 (pt) 2011-03-01
HK1120732A1 (en) 2009-04-09
MX2008000079A (es) 2008-03-19
HUE030264T2 (en) 2017-04-28
ES2610472T3 (es) 2017-04-27
UA88701C2 (ru) 2009-11-10
TW200800183A (en) 2008-01-01
WO2007000434A1 (en) 2007-01-04
KR101329587B1 (ko) 2013-11-15
EA014431B1 (ru) 2010-12-30
EP1898909B1 (en) 2016-10-19
EP1898909A1 (en) 2008-03-19
NZ564340A (en) 2011-02-25
BRPI0613999B1 (pt) 2020-04-22
JP5193857B2 (ja) 2013-05-08
AU2006263882A1 (en) 2007-01-04
NO20080499L (no) 2008-02-29
CA2612614A1 (en) 2007-01-04
TWI413520B (zh) 2013-11-01
NO341285B1 (no) 2017-10-02
PT1898909T (pt) 2016-12-07
SG166798A1 (en) 2010-12-29
KR20080028459A (ko) 2008-03-31
PL1898909T3 (pl) 2017-03-31
ZA200711148B (en) 2013-03-27
JO3322B1 (ar) 2019-03-13
RS55601B1 (sr) 2017-06-30
BRPI0613999B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1119402T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1120081T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
CY1117766T1 (el) Αντιβακτηριδιακα παραγωγα κινολινης
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CY1124086T1 (el) Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1109644T1 (el) 2,4-διαμινο-πυριμιδινες ως αναστολεις audora
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
CY1115199T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση
CY1110127T1 (el) Υποκατεστημενες 1-προπιολυλο-πιπεραζινες με χημικη συγγενεια για τον υποδοχεα mglur5 για τη θεραπεια καταστασεων πονου
CY1114318T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
BRPI0716598A2 (pt) Derivados de (hetero) arilsulfonamida de n-biarila úteis no tratamento de doenças medidas por interações de linfócitos
CR9113A (es) Compuestos acetamida como fungicidas
CY1115227T1 (el) Νεοι καταστολεις φωσφοδιεστερασης (phosphodiesterase)
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
CY1118515T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
ECSP10010014A (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
CY1111830T1 (el) Παραγωγα πυριδινης ως ρυθμιστες υποδοχεων s1p1/edg1
CY1113244T1 (el) Ενωση ουρακιλης η οποια εχει ανασταλτικη δραστικοτητα σε ανθρωπινη τριφωσφαταση δεοξυουριδινης ή αλας αυτης
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
MX2019009354A (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer.
CY1124577T1 (el) Καινοτομες ενωσεις τετραζολιου και η χρηση τους στη θεραπεια της φυματιωσης
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης